Drug Research
Recro and BioCorRx expand partnership for OUD treatment
Recro Pharma, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, and BioCorRx, Inc., a developer and provider of advanced solutions in the treatment of substance use...
Drug Research
Repligen and Navigo GmbH Announce Launch of Industry First Protein A Ligand for Purification of pH Sensitive Antibodies
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH announced they have completed development and validation of a novel protein A ligand that overcomes challenges associated with the purification of pH sensitive antibodies...
Drug Research
GeneQuine Selects Exothera to Support the Next Stage of Its Osteoarthritis Gene Therapy Development
GeneQuine Biotherapeutics GmbH, a biotech company focused on the development of gene therapy for musculoskeletal disorders, announced that it has contracted Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), to conduct a feasibility study for the development...
Drug Research
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic...
Drug Research
Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential
Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, announced a four-year collaboration with the Bill & Melinda Gates Foundation, a non-profit focused on fighting global poverty, disease, and inequity, to develop small...
Drug Research
EnGeneIC develops world-first nanocellular anti-COVID-19 vaccine that defeats mutant viruses and stimulates a broad anti-viral response
EnGeneIC Limited, an Australian, Sydney-based biotechnology company, has developed a globally unique nanocellular technology that in pre-clinical animal studies has been shown to stimulate a broad and powerful anti-COVID-19 immune response and also neutralises the known mutant COVID-19 viruses...
Drug Research
NeuExcell and Spark partner to develop gene therapy for Huntingtons Disease
NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD).
Under the terms of the agreement, Spark Therapeutics will...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read